Coronavirus disease 2019 (COVID-19) displays a broad spectrum of clinical presentations ranging from lack of symptoms to severe multiorgan system complications and death. Various laboratory assays have been employed in the diagnosis of COVID-19, including: nucleic acid-based tests; antigen tests; and serum testing for anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies. The disease can also be diagnosed based on suggestive clinical features and radiological findings. Until now, remdesivir is the only medication approved for the treatment of COVID-19 by the U.S. Food and Drug Administration (FDA); however, it is anticipated that several anti-SARS-CoV-2 monoclonal antibodies will gain soon approval. Other methods of treatment include supportive care directed toward treating the symptoms. Nevertheless, many studies have recently emerged, showing controversial preliminary results with the off-label medication hydroxychloroquine. Given that all results are still preliminary, including those seen by remdesivir, additional evidence and research are required to identify effective medications that are broadly effective and well tolerated. Importantly, two RNA-based vaccines have recently gained approval from Pfizer and Moderna, with many others still in clinical trials. This article reviews various aspects of COVID-19, including its epidemiology; its evolution and mutational spectrum; and its clinical dynamics, symptoms and complications, diagnosis, and treatment.

中文翻译：

---

冠状病毒病2019大流行时代：动力学，临床症状和并发症，诊断和治疗的评论

2019年冠状病毒病（COVID-19）显示了广泛的临床表现，从缺乏症状到严重的多器官系统并发症和死亡。在COVID-19的诊断中已采用了各种实验室检测方法，包括：基于核酸的检测；抗原测试；抗严重急性呼吸系统综合症冠状病毒2（SARS-CoV-2）抗体的血清和血清检测。也可以根据提示的临床特征和影像学发现来诊断疾病。到目前为止，雷姆昔韦是美国食品和药物管理局（FDA）批准用于治疗COVID-19的唯一药物。但是，预计几种抗SARS-CoV-2单克隆抗体将很快获得批准。其他治疗方法包括针对症状的支持治疗。尽管如此，最近出现了许多研究，显示了标签外药物羟氯喹的有争议的初步结果。鉴于所有结果仍是初步的，包括雷姆昔韦观察到的结果，还需要其他证据和研究来鉴定广泛有效且耐受性良好的有效药物。重要的是，两种基于RNA的疫苗最近已获得辉瑞和Moderna的批准，许多其他疫苗仍在临床试验中。本文回顾了COVID-19的各个方面，包括其流行病学；它的进化和突变谱；及其临床动态，症状和并发症，诊断和治疗。需要更多的证据和研究来鉴定广泛有效且耐受性良好的有效药物。重要的是，两种基于RNA的疫苗最近已获得辉瑞和Moderna的批准，许多其他疫苗仍在临床试验中。本文回顾了COVID-19的各个方面，包括其流行病学；它的进化和突变谱；及其临床动态，症状和并发症，诊断和治疗。需要更多的证据和研究来鉴定广泛有效且耐受性良好的有效药物。重要的是，两种基于RNA的疫苗最近已获得辉瑞和Moderna的批准，许多其他疫苗仍在临床试验中。本文回顾了COVID-19的各个方面，包括其流行病学；它的进化和突变谱；及其临床动态，症状和并发症，诊断和治疗。